$GYRE News

Gyre Therapeutics New Drug Application For Chronic Hepatitis B Treatment Receives China's Center For Drug Evaluation Acceptance

Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $137.033M Est

Gyre Therapeutics Q1 Adj. EPS $(0.04) Beats $(0.07) Estimate, Sales $22.519M Miss $31.607M Estimate

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

Gyre Therapeutics Gets Priority Review In China For Hepatitis B Liver Damage Drug

Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Gyre Therapeutics Sees FY2026 Sales $100.500M-$111.000M vs $146.133M Est

Gyre Therapeutics Q4 Adj. EPS $0.05 Misses $0.06 Estimate, Sales $37.195M Beat $36.303M Estimate

Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates

Gyre Therapeutics shares are trading higher after the company announced it agreed to acquire Cullgen for approximately $300 million.

Gyre Therapeutics shares are trading higher after the company announced it agreed to acquire Cullgen for approximately $300 million.

Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline

Gyre Therapeutics Strikes All-Stock Agreement To Acquire Cullgen For ~$300M

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates

Gyre Therapeutics shares are trading higher after its subsidiary, Gyre Pharmaceuticals, completed a Pre-NDA meeting with China's CDE on its anti-fibrotic therapy Hydronidone. The company plans to submit an NDA in the first half of 2026 and launch a confirmatory clinical trial to support full approval in China.

Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting

Gyre Therapeutics Aligns With China CDE On Conditional Approval Pathway And Priority Review For Hydronidone